CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Open-market sale Director sold 120,592 shares at an average $29.29 ($3,531,820)
- 4 Open-market sale Zawel Leigh sold 28,118 shares at $29.00 ($815,422)
- 4 Open-market sale Michaelson Jennifer sold 4,000 shares at an average $27.66 ($110,648)
- 4 Open-market sale 10% owner sold 2,510 shares at $29.05 ($72,916)
- 4 Open-market sale Director sold 2,857 shares at $29.05 ($82,996)
- 4 Open-market sale Zawel Leigh sold 28,118 shares at an average $26.77 ($752,850)
- 4 Open-market buy 10% owner bought 300,000 shares at $21.00 ($6,300,000)
- 4 Open-market buy Director bought 300,000 shares at $21.00 ($6,300,000)
- 3/A Insider 3/A
- 4 Open-market buy Director bought 200,000 shares at $21.00 ($4,200,000)
- 4 Open-market buy President and CEO bought 2,500 shares at $21.00 ($52,500)
- 4 Open-market buy Chief Financial Officer bought 2,250 shares at $21.00 ($47,250)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
Page 12 of 13 · 253 filings